Hinova Pharmaceuticals Inc. A - Asset Resilience Ratio

Latest as of June 2025: 15.84%

Hinova Pharmaceuticals Inc. A (688302) has an Asset Resilience Ratio of 15.84% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Hinova Pharmaceuticals Inc. A total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥220.52 Million

≈ $32.27 Million USD Cash + Short-term Investments

Total Assets

CN¥1.39 Billion

≈ $203.78 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Hinova Pharmaceuticals Inc. A's Asset Resilience Ratio has changed over time. See Hinova Pharmaceuticals Inc. A shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Hinova Pharmaceuticals Inc. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Hinova Pharmaceuticals Inc. A.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥220.52 Million	15.84%
Total Liquid Assets	CN¥220.52 Million	15.84%

Asset Resilience Insights

Good Liquidity Position: Hinova Pharmaceuticals Inc. A maintains a healthy 15.84% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Hinova Pharmaceuticals Inc. A Industry Peers by Asset Resilience Ratio

Compare Hinova Pharmaceuticals Inc. A's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.10%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	30.29%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	4.52%
Shanghai Junshi Biosciences Co Ltd SHG:688180	Biotechnology	4.28%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	83.49%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	41.74%

Annual Asset Resilience Ratio for Hinova Pharmaceuticals Inc. A (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Hinova Pharmaceuticals Inc. A.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	15.46%	CN¥210.49 Million ≈ $30.80 Million	CN¥1.36 Billion ≈ $199.24 Million	-4.03pp
2023-12-31	19.48%	CN¥290.62 Million ≈ $42.53 Million	CN¥1.49 Billion ≈ $218.26 Million	-1.62pp
2022-12-31	21.11%	CN¥366.24 Million ≈ $53.59 Million	CN¥1.74 Billion ≈ $253.90 Million	+13.28pp
2019-12-31	7.83%	CN¥3.50 Million ≈ $512.16K	CN¥44.72 Million ≈ $6.54 Million	--

pp = percentage points

About Hinova Pharmaceuticals Inc. A

SHG:688302 China Biotechnology

Market Cap

$638.39 Million

CN¥4.36 Billion CNY

Market Cap Rank

#11338 Global

#3407 in China

Share Price

CN¥44.06

Change (1 day)

+0.14%

52-Week Range

CN¥36.52 - CN¥67.20

All Time High

CN¥74.97